Every year, the global medical device market is undergoing rapid growth, not only in the hospital industry but in the health care industry in general. In the Asia-Pacific region, the growth rate is particularly high at more than 12 percent over the past five years, the fastest market growth rate in the world. Within this rapidly changing market, the technology that has managed to captivate the world’s attention is Seegene’s molecular diagnostic technology (MuDT™). The success of this remarkable technology is one of several factors currently motivating Seegene to aggressively promote its products and status at large-scale international conferences overseas and one of the reasons it has been recognized within Korean academia.

On October 15, the fall conference of The Korean Society for Laboratory Medicine (KSLM) was held at the Kimdaejung Convention Center in Gwangju, where Seegene’s Allplex™ products were introduced. These products are based on a new technology (MuDT™) that enables the simultaneous detection and quantification of multiple targets in a single channel, something that was not possible with existing real-time PCR technology.

The two Allplex™ products introduced at this year’s KSLM conference are each composed of four panels, and each panel includes similar pathogens, enabling an effective diagnosis that is best suited to each patient’s particular condition. They are capable of detecting 26 types of respiratory pathogens and 26 types of pathogens that cause gastrointestinal disease. The Allplex™ product line has already received CE certification in Europe and is being used at major large hospitals and diagnostic centers. Also, the number of institutions using Allplex™ products in the Middle East, Asia, and the America is rapidly increasing, while preparations are being made for the product line’s domestic release in 2016.